ATE245993T1 - Allosterische modulatoren des nmda-rezeptors - Google Patents
Allosterische modulatoren des nmda-rezeptorsInfo
- Publication number
- ATE245993T1 ATE245993T1 AT95936300T AT95936300T ATE245993T1 AT E245993 T1 ATE245993 T1 AT E245993T1 AT 95936300 T AT95936300 T AT 95936300T AT 95936300 T AT95936300 T AT 95936300T AT E245993 T1 ATE245993 T1 AT E245993T1
- Authority
- AT
- Austria
- Prior art keywords
- nmda receptor
- allosteric modulators
- compositions
- methods
- receptor function
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 3
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 101710191405 Conantokin-G Proteins 0.000 abstract 1
- HTBKFGWATIYCSF-QGXIKSNHSA-N conantokin g Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN HTBKFGWATIYCSF-QGXIKSNHSA-N 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Liquid Crystal Substances (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/323,436 US5830998A (en) | 1992-09-28 | 1994-10-14 | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| US08/413,490 US5854217A (en) | 1992-09-28 | 1995-03-30 | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| PCT/US1995/013037 WO1996011698A1 (en) | 1994-10-14 | 1995-10-13 | Allosteric modulators of the nmda receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE245993T1 true ATE245993T1 (de) | 2003-08-15 |
Family
ID=26983959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95936300T ATE245993T1 (de) | 1994-10-14 | 1995-10-13 | Allosterische modulatoren des nmda-rezeptors |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US5854217A (de) |
| EP (1) | EP0785793B1 (de) |
| JP (1) | JP3273792B2 (de) |
| AT (1) | ATE245993T1 (de) |
| CA (1) | CA2202513C (de) |
| DE (1) | DE69531403D1 (de) |
| WO (1) | WO1996011698A1 (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854217A (en) | 1992-09-28 | 1998-12-29 | Bearsden Bio, Inc. | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| US5763393A (en) * | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| US6515103B1 (en) | 1996-07-22 | 2003-02-04 | University Of Utah Research Foundation | Conantokins |
| US6277825B1 (en) | 1996-07-22 | 2001-08-21 | University Of Utah Research Foundation | Use of conantokins for treating pain |
| JP2002513380A (ja) | 1996-07-22 | 2002-05-08 | コグネティックス・インコーポレイテッド | コナントキンの使用 |
| WO1998036743A1 (en) * | 1997-02-21 | 1998-08-27 | Cypros Pharmaceutical Corporation | Neuroprotective poly-guanidino compounds which block presynaptic n and p/q calcium channels |
| US5844077A (en) * | 1997-04-28 | 1998-12-01 | Cytotherapeutics, Inc. | Use of conantokins for producing analgesia or for neuroprotection |
| US6197535B1 (en) | 1998-02-10 | 2001-03-06 | University Of Utah Research Foundation | Methods for purifying and assaying a conus γ-carboxylase |
| EP1214335A4 (de) * | 1999-09-10 | 2003-04-23 | Univ Utah Res Found | Gamma-carboxyglutamat enhaltende conopeptide |
| US6399574B1 (en) | 2000-03-22 | 2002-06-04 | University Of Utah Research Foundation | Use of conantokins |
| CA2419285C (en) * | 2000-08-25 | 2011-08-02 | Research Corporation Technologies, Inc. | New uses for amino acid anticonvulsants |
| US20030065138A1 (en) * | 2001-03-07 | 2003-04-03 | University Of Utah Research Foundation | Linear gamma-carboxyglutamate rich conotoxins |
| ATE519485T1 (de) * | 2001-03-29 | 2011-08-15 | Michael Davis | Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine |
| US20070197583A1 (en) * | 2002-03-29 | 2007-08-23 | Welsh Michael J | Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction |
| US20030186860A1 (en) * | 2002-03-29 | 2003-10-02 | Welsh Michael J. | Novel compositions and methods for modulating the acid-sensing ion channel (ASIC) |
| US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| AU2002952993A0 (en) | 2002-11-29 | 2002-12-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Therapeutic and diagnostic agents |
| AU2003901325A0 (en) | 2003-03-21 | 2003-04-03 | Stephen Locarnini | Therapeutic, prophylactic and diagnostic agents |
| WO2005020677A1 (en) | 2003-08-29 | 2005-03-10 | The Walter And Eliza Hall Institute Of Medical Research | Method of selecting animal models from animals which have been subject to mutagenesis, and the use of myb transcription factors for screening |
| US7176185B2 (en) * | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
| CA2551189A1 (en) | 2003-12-24 | 2005-07-07 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic agents and uses therefor |
| NZ551828A (en) | 2004-05-12 | 2009-03-31 | Inst Medical W & E Hall | A method of cell isolating a homogenous population of mammary stem cells using specific cell surface marker proteins |
| EP1910535B1 (de) | 2005-06-24 | 2016-08-17 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutische pro-apoptose-bh3-ähnliche moleküle und verfahren zur erzeugung und/oder auswahl davon |
| CN100341566C (zh) * | 2005-12-29 | 2007-10-10 | 中国人民解放军军事医学科学院生物工程研究所 | 芋螺多肽衍生物用于制备戒毒药物的用途 |
| CN101426536A (zh) | 2006-01-20 | 2009-05-06 | 妇女儿童健康研究院公司 | 治疗、预防和诊断骨病变的方法 |
| JP5558817B2 (ja) | 2006-07-18 | 2014-07-23 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | 痛みの処置方法および鎮痛化合物のスクリーニング方法 |
| US20090291150A1 (en) * | 2008-05-21 | 2009-11-26 | University Of Iowa Research Foundation | Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity |
| BRPI0902039B8 (pt) | 2009-06-09 | 2021-05-25 | Anhanguera Educacional Ltda | composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais |
| EP2260864A1 (de) | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutische Anwendungen |
| JP6152944B2 (ja) | 2010-06-23 | 2017-06-28 | モナシュ、ユニバーシティＭｏｎａｓｈ Ｕｎｉｖｅｒｓｉｔｙ | 束縛免疫原性組成物およびその用途 |
| US9079950B2 (en) | 2010-08-04 | 2015-07-14 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Modified Hepatitis C virus proteins |
| CN104324373B (zh) | 2010-11-26 | 2018-10-09 | 麦克法兰博尼特医学健康研究公司 | 组合物及其制备方法 |
| JP6681826B2 (ja) | 2013-05-31 | 2020-04-15 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション | コノトキシンペプチド、医薬組成物およびそれらの使用 |
| WO2016149248A1 (en) | 2015-03-15 | 2016-09-22 | Emory University | N-methyl-d-aspartate receptor (nmdar) potentiators, pharmaceutical compositions, and uses related thereto |
| US10111554B2 (en) | 2015-03-20 | 2018-10-30 | Meltz, LLC | Systems for and methods of controlled liquid food or beverage product creation |
| US10314320B2 (en) | 2015-03-20 | 2019-06-11 | Meltz, LLC | Systems for controlled liquid food or beverage product creation |
| JP6877419B2 (ja) | 2015-10-27 | 2021-05-26 | ザ ユニバーシティー オブ クイーンズランド | 治療の方法およびそのために有用な剤 |
| WO2017109756A2 (es) * | 2015-12-22 | 2017-06-29 | Universidad Nacional De Colombia | Péptidos sintéticos moduladores del receptor nmda |
| EP3526230A4 (de) | 2016-10-12 | 2020-11-25 | Glycosynnovations Pty Ltd | Therapeutika und verfahren zur herstellung davon |
| WO2018071977A1 (en) * | 2016-10-20 | 2018-04-26 | Memphasys Limited | Electrophoresis device |
| JP2020517400A (ja) | 2017-04-27 | 2020-06-18 | コミティア，インク． | 遠心分離抽出のための方法および本方法を実行するために好適な装置 |
| US11724849B2 (en) | 2019-06-07 | 2023-08-15 | Cometeer, Inc. | Packaging and method for single serve beverage product |
| WO2021137245A1 (en) | 2020-01-05 | 2021-07-08 | Technion Research & Development Foundation Limited | Conus-based toxin peptides, nucleic acids encoding same and uses thereof in modulating nmda receptors |
| PH12022551856A1 (en) | 2020-01-22 | 2024-01-03 | Seelos Therapeutics Inc | Reducing side effects of nmda antagonists |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5051413A (en) | 1986-02-13 | 1991-09-24 | Ciba-Geigy Corporation | Unsaturated amino acids |
| US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
| CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
| US5049555A (en) | 1988-12-19 | 1991-09-17 | Nova Pharmaceutical Corporation | Antagonists of specific excitatory amino acid receptors as neuroprotectants and anxiolytics |
| US5061721A (en) * | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US6017957A (en) * | 1989-08-08 | 2000-01-25 | The United States Of America As Represented By The Department Of Health And Human Services | Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents |
| US5051403A (en) * | 1989-11-22 | 1991-09-24 | Neurex Corporation | Method of treating ischemia-related neuronal damage |
| US5559095A (en) * | 1989-11-22 | 1996-09-24 | Neurex Corporation | Delayed treatment method of reducing ischemia-related neuronal damage |
| US5086072A (en) * | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| GB9109007D0 (en) | 1991-04-26 | 1991-06-12 | Merck Sharp & Dohme | Therapeutic method |
| CA2115442C (en) | 1991-09-09 | 2003-09-23 | Christopher Franklin Bigge | Pharmaceutical preparation containing an uricosuric agent and an excitatory amino acid antagonist |
| JPH07505908A (ja) * | 1992-09-28 | 1995-06-29 | マックセチーニ、マリア ルイザ | Ｎｍｄａ受容体のアロステリックモジュレーター |
| US5854217A (en) | 1992-09-28 | 1998-12-29 | Bearsden Bio, Inc. | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| US5428069A (en) | 1993-01-11 | 1995-06-27 | The United States Of America As Represented By The Department Of Health & Human Services | Treating cognition with, aminocyclopropanecarboxylic derivatives |
| US5432155A (en) | 1993-06-29 | 1995-07-11 | The Salk Institute For Biological Studies | Conotoxins I |
| US5523323A (en) * | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
| DE19543478A1 (de) * | 1995-11-22 | 1997-05-28 | Bayer Ag | Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman |
| JP2002513380A (ja) * | 1996-07-22 | 2002-05-08 | コグネティックス・インコーポレイテッド | コナントキンの使用 |
| US5844077A (en) * | 1997-04-28 | 1998-12-01 | Cytotherapeutics, Inc. | Use of conantokins for producing analgesia or for neuroprotection |
-
1995
- 1995-03-30 US US08/413,490 patent/US5854217A/en not_active Expired - Fee Related
- 1995-10-13 CA CA002202513A patent/CA2202513C/en not_active Expired - Fee Related
- 1995-10-13 JP JP51336396A patent/JP3273792B2/ja not_active Expired - Fee Related
- 1995-10-13 WO PCT/US1995/013037 patent/WO1996011698A1/en not_active Ceased
- 1995-10-13 AT AT95936300T patent/ATE245993T1/de not_active IP Right Cessation
- 1995-10-13 DE DE69531403T patent/DE69531403D1/de not_active Expired - Lifetime
- 1995-10-13 EP EP95936300A patent/EP0785793B1/de not_active Expired - Lifetime
-
1998
- 1998-09-03 US US09/146,269 patent/US6110894A/en not_active Expired - Fee Related
- 1998-09-03 US US09/146,268 patent/US6284731B1/en not_active Expired - Fee Related
-
2000
- 2000-04-20 US US09/553,042 patent/US6511963B1/en not_active Expired - Fee Related
-
2002
- 2002-11-25 US US10/302,971 patent/US20030134799A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2202513A1 (en) | 1996-04-25 |
| JPH10504316A (ja) | 1998-04-28 |
| WO1996011698A1 (en) | 1996-04-25 |
| EP0785793B1 (de) | 2003-07-30 |
| US5854217A (en) | 1998-12-29 |
| JP3273792B2 (ja) | 2002-04-15 |
| DE69531403D1 (de) | 2003-09-04 |
| US6511963B1 (en) | 2003-01-28 |
| US6110894A (en) | 2000-08-29 |
| CA2202513C (en) | 2002-08-13 |
| US6284731B1 (en) | 2001-09-04 |
| EP0785793A1 (de) | 1997-07-30 |
| US20030134799A1 (en) | 2003-07-17 |
| EP0785793A4 (de) | 2000-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69531403D1 (de) | Allosterische modulatoren des nmda-rezeptors | |
| NO986100L (no) | Androgene reseptormodulerende forbindelser og fremgangsmÕter | |
| BR9510486A (pt) | Compostos moduladores de receptores de esteróide e métodos | |
| MY141384A (en) | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | |
| EP0911321A3 (de) | Verbindungen zur Behandlung von Osteoporose | |
| MY129189A (en) | Prostaglandin agonists and their use to treat bone disorders | |
| MX9704640A (es) | Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion. | |
| FI20051271L (fi) | Yhdisteet ja koostumukset GABA-reseptorin allosteeriseksi moduloimiseksi | |
| AP9801269A0 (en) | Prostaglandin agonists. | |
| DK0841928T3 (da) | Sustained release-formulering af d-threo-methylphenidat | |
| AU2002345497A1 (en) | Cips as modifiers of the p53 pathway and method of use | |
| JO2359B1 (en) | Benzathene derivatives as agents for modulation of GABA A receptor | |
| GB9712966D0 (en) | Novel chalcones | |
| BR9708347A (pt) | Compostos de tetrahidorbeta-carbonila | |
| DE69332605D1 (de) | Allosterische modulatoren des nmda-rezeptors | |
| DE69808475D1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| BR9714189A (pt) | N-(piridinilamino) isoindolinas e compostos relacionados | |
| ID27964A (id) | Turuna-azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |